國立虎尾科技大學 |

Management of Chemotherapy-Induced Nausea and Vomiting = New Agents and New Uses of Current Agents /

Record Type:	Language materials, printed : Monograph/item
Title/Author:	Management of Chemotherapy-Induced Nausea and Vomiting/ edited by Rudolph M. Navari.
Reminder of title:	New Agents and New Uses of Current Agents /
other author:	Navari, Rudolph M.
Description:	VIII, 181 p. 17 illus., 8 illus. in color.online resource. :
Contained By:	Springer Nature eBook
Subject:	Oncology . -
Online resource:	https://doi.org/10.1007/978-3-319-27016-6
ISBN:	9783319270166

Management of Chemotherapy-Induced Nausea and Vomiting = New Agents and New Uses of Current Agents /
Management of Chemotherapy-Induced Nausea and VomitingNew Agents and New Uses of Current Agents /[electronic resource] :edited by Rudolph M. Navari. - 1st ed. 2016. - VIII, 181 p. 17 illus., 8 illus. in color.online resource.

1. Introduction -- 2. The Physiology and Pharmacology of Nausea and Vomiting Induced by Anti-Cancer Chemotherapy in Humans -- 3. First Generation 5HT-3 Receptor Antagonists -- 4. Second Generation Serotonin (5-HT3) Receptor Antagonist Palonosetron -- 5. The Role of Neurokinin-1 Receptor Antagonists in CINV -- 6. Olanzapine for the prevention of Chemotherapy-Induced Nausea and Vomiting -- 7. Gabapentin for the Prevention of CINV -- 8. Prevention of CINV in Patients Receiving High-Dose Multiple-Day Chemotherapy -- 9. Clinical Management of CINV -- 10. Treatment of Chemotherapy-Induced Nausea -- 11. Conclusions -- 12. Future Directions.

This book provides a comprehensive review of new agents, a detailed description of new uses of current agents, and an integration of the available agents in clinical practice. A description of a detailed clinical approach provides clinical practitioners with the most up-to-date recommendations for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV) in various clinical settings. CINV is one of the most feared treatment related toxicities. Patient surveys for the past thirty years consistently demonstrate patients’ perception of deterioration in quality of life due to chemotherapy treatments. The introduction of the antiemetics, serotonin 5-HT3 receptor antagonists and the neurokinin-1 receptor antagonists, have improved the control of chemotherapy-induced emesis, but the treatment of chemotherapy-induced nausea remains a significant clinical problem. Patients continue to have quality of life issues which prevent normal functioning during active treatment. New agents such as the second generation 5-HT3 receptor antagonist palonosetron and the new neuroknin-1 receptor antagonists rolapitant and netupitant are being introduced into clinical practice, and it is anticipated that these new agents will improve the control of CINV. Agents such as olanzapine (a FDA approved anti-psychotic), gabapentin (a FDA approved neuroleptic), and ginger (a food additive), which have been used primarily for other indications, are now being tested as potential, effective antiemetics. This work represents the first available comprehensive summary that details all new antiemetic agents and, particularly, their clinical role in treating patients; an important reference for practitioners seeking to improve the quality of life of patients undergoing chemotherapy.

ISBN: 9783319270166

Standard No.: 10.1007/978-3-319-27016-6doiSubjects--Topical Terms:

1253469
Oncology .

LC Class. No.: RC254-282

Dewey Class. No.: 616.994

Management of Chemotherapy-Induced Nausea and Vomiting = New Agents and New Uses of Current Agents /
LDR:03815nam a22003975i 4500 001 980452
003 DE-He213
005 20200702092843.0
007 cr nn 008mamaa
008 201211s2016 gw | s |||| 0|eng d
020 $a 9783319270166 $9 978-3-319-27016-6
024 7 $a 10.1007/978-3-319-27016-6 $2 doi
035 $a 978-3-319-27016-6
050 4 $a RC254-282
072 7 $a MJCL $2 bicssc
072 7 $a MED062000 $2 bisacsh
072 7 $a MJCL $2 thema
082 0 4 $a 616.994 $2 23
245 1 0 $a Management of Chemotherapy-Induced Nausea and Vomiting $h [electronic resource] : $b New Agents and New Uses of Current Agents / $c edited by Rudolph M. Navari.
250 $a 1st ed. 2016.
264 1 $a Cham : $b Springer International Publishing : $b Imprint: Adis, $c 2016.
300 $a VIII, 181 p. 17 illus., 8 illus. in color. $b online resource.
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
347 $a text file $b PDF $2 rda
505 0 $a 1. Introduction -- 2. The Physiology and Pharmacology of Nausea and Vomiting Induced by Anti-Cancer Chemotherapy in Humans -- 3. First Generation 5HT-3 Receptor Antagonists -- 4. Second Generation Serotonin (5-HT3) Receptor Antagonist Palonosetron -- 5. The Role of Neurokinin-1 Receptor Antagonists in CINV -- 6. Olanzapine for the prevention of Chemotherapy-Induced Nausea and Vomiting -- 7. Gabapentin for the Prevention of CINV -- 8. Prevention of CINV in Patients Receiving High-Dose Multiple-Day Chemotherapy -- 9. Clinical Management of CINV -- 10. Treatment of Chemotherapy-Induced Nausea -- 11. Conclusions -- 12. Future Directions.
520 $a This book provides a comprehensive review of new agents, a detailed description of new uses of current agents, and an integration of the available agents in clinical practice. A description of a detailed clinical approach provides clinical practitioners with the most up-to-date recommendations for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV) in various clinical settings. CINV is one of the most feared treatment related toxicities. Patient surveys for the past thirty years consistently demonstrate patients’ perception of deterioration in quality of life due to chemotherapy treatments. The introduction of the antiemetics, serotonin 5-HT3 receptor antagonists and the neurokinin-1 receptor antagonists, have improved the control of chemotherapy-induced emesis, but the treatment of chemotherapy-induced nausea remains a significant clinical problem. Patients continue to have quality of life issues which prevent normal functioning during active treatment. New agents such as the second generation 5-HT3 receptor antagonist palonosetron and the new neuroknin-1 receptor antagonists rolapitant and netupitant are being introduced into clinical practice, and it is anticipated that these new agents will improve the control of CINV. Agents such as olanzapine (a FDA approved anti-psychotic), gabapentin (a FDA approved neuroleptic), and ginger (a food additive), which have been used primarily for other indications, are now being tested as potential, effective antiemetics. This work represents the first available comprehensive summary that details all new antiemetic agents and, particularly, their clinical role in treating patients; an important reference for practitioners seeking to improve the quality of life of patients undergoing chemotherapy.
650 0 $a Oncology . $3 1253469
650 0 $a Pharmacology. $3 583819
650 0 $a Pharmacotherapy. $3 973587
650 1 4 $a Oncology. $3 593951
650 2 4 $a Pharmacology/Toxicology. $3 593882
700 1 $a Navari, Rudolph M. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1105529
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer Nature eBook
776 0 8 $i Printed edition: $z 9783319270142
776 0 8 $i Printed edition: $z 9783319270159
776 0 8 $i Printed edition: $z 9783319800585
856 4 0 $u https://doi.org/10.1007/978-3-319-27016-6
912 $a ZDB-2-SME
912 $a ZDB-2-SXM
950 $a Medicine (SpringerNature-11650)
950 $a Medicine (R0) (SpringerNature-43714)